5466-00-2

Usage

Uses

5,6-Trimethyleneuracil can be used as VCP/p97 inhibitors.

Synthesis Reference(s)

Tetrahedron Letters, 17, p. 4379, 1976 DOI: 10.1016/0040-4039(76)80121-9

InChI:InChI=1/C7H8N2O2/c10-6-4-2-1-3-5(4)8-7(11)9-6/h1-3H2,(H2,8,9,10,11)

Upstream product

• 35563-27-0 2-sulfanylidene-1,2,3,4,6,7-hexahydro-5H-cyclopenta[d]pyrimidin-4-one 
• 33081-06-0 2-amino-6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one 
• 611-10-9 2-ethoxycarbonyl-1-cyclopentanone 
• 57-13-6 urea 
• 160234-22-0 2-ethtylthiocyclopentanopyrimidin-4-one 
• 122364-77-6 2-Ureido-cyclopent-1-enecarboxylic acid butyl ester 
• 10472-24-9 methyl 2-oxocyclopentane-1-carboxylate 
• 1196101-51-5 methyl 2-ureidocyclopentene-1-carboxylate 
• 3087-14-7 2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol 
• 18227-09-3 2-ureido-1-carbethoxycyclopent-1-ene 

Downstream Products

• 49786-32-5 5,6-trimethylene-1,3-dimethyluracil 
• 132332-56-0 1-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-1,5,6,7-tetrahydro-cyclopentapyrimidine-2,4-dione; hydrochloride 
• 160234-23-1 1-(benzyloxymethyl)-cyclopentanopyrimidine-2,4-dione 
• 389888-02-2 (S)-CPW 399 
• 1616389-35-5 (4R)-1-(2,4-dioxo-3,4,6,7-tetrahydro-2H-cyclopenta[d]pyrimidin-1(5H)-yl)-3-((3-methoxyphenyl)(4-methoxyphenyl)(phenyl)methoxy)-propan-2-yl-P-2-cyanoethyl-N,N-cianopropylphosphonamidate 
• 1616389-36-6 (4S)-1-(2,4-dioxo-3,4,6,7-tetrahydro-2H-cyclopenta[d]pyrimidin-1(5H)-yl)-3-((3-methoxyphenyl)(4-methoxyphenyl)(phenyl)methoxy)-propan-2-yl-P-2-cyanoethyl-N,N-cianopropylphosphonamidate 
• 1651865-12-1 C₃₁H₃₂N₂O₆ 
• 1651865-13-2 C₃₁H₃₂N₂O₆ 
• 1621363-03-8 4-(2-(3-fluoro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yloxy)benzoic acid methyl ester 
• 1621363-36-7 2-(4-(2-(thiazol-5-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yloxy)phenyl)acetic acid methylester 
• 1621362-84-2 2-(4-(2-(thiazol-5-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yloxy)phenyl)acetic acid 
• 1621363-37-8 2-(4-(2-bromo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yloxy)phenyl)acetic acid methyl ester 
• 1621362-85-3 2-(4-(2-(2-chlorothiazol-5-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yloxy)phenyl)acetic acid 
• 1621363-38-9 2-(4-(2-(5-cyanothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yloxy)phenyl)acetic acid methyl ester 

Relevant academic research and scientific papers

Formation of 5,6-cyclopentano-uracil by cyclization of the bisamide of adipic acid induced by oxalyl chloride

Cyclization of the bisamide of adipic acid induced by oxalyl chloride will eventually yield a product of the composition C9H8N2O5, which upon hydrolysis gave 5,6-cyclo-pentanouracil. The structures of both compounds were established by X-ray crystallography.

Synthesis of new 6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione derivatives containing the substituted aliphatic ring

The bromination of 6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione (1) resulted in the substitution in the aliphatic ring. The reaction of this product with different N-nucleophiles gives new derivatives of the starting compound. The direction of

Discovery of novel pyrimidine molecules containing boronic acid as VCP/p97 Inhibitors

Valine-containing protein (VCP) is a member of the adenosine triphosphate family involved in a variety of cellular activities. VCP/p97 is capable of maintaining protein homeostasis and mediating the degradation of misfolded polypeptides by the ubiquitin–proteasome system (UPS). In this manuscript, a series of novel p97 inhibitors with pyrimidine as core structure were designed, synthesized and biologically evaluated. Based on the enzymatic results, a detailed structure–activity relationship discussion of the synthesized compounds was carried out. Furthermore, cellular activities of the compounds with enzymatic potency of less than 200 nM were investigated by using A549 and RPMI8226 cell lines. Among the screened inhibitors, compound 17 (IC50, 54.7 nM) showed good enzymatic activity. Investigation of cellular activities with non-small cell lung cancer A549 and multiple myeloma (MM) RPMI8226 further confirmed the potency of 17 with the IC50 values of 2.80 μM and 0.86 μM, respectively. Compound 17 is now being developed as a candidate. Finally, docking studies were carried out to explore the possible binding mode between the active inhibitor 17 and p97.

Matrix Metalloproteinase 13 Inhibitors for Modulation of Osteoclastogenesis: Enhancement of Solubility and Stability

Matrix metalloproteinase 13 (MMP-13) activity has been correlated to breast cancer bone metastasis. It has been proposed that MMP-13 contributes to bone metastasis through the promotion of osteoclastogenesis. To explore the mechanisms of MMP-13 action, we previously described a highly efficacious and selective MMP-13 inhibitor, RF036. Unfortunately, further pursuit of RF036 as a probe of MMP-13 in vitro and in vivo activities was not practical due to the limited solubility and stability of the inhibitor. Our new study has explored replacing the RF036 backbone sulfur atom and terminal methyl group to create inhibitors with more favorable pharmacokinetic properties. One compound, designated inhibitor 3, in which the backbone sulfur and terminal methyl group of RF036 were replaced by nitrogen and oxetane, respectively, had comparable activity, selectivity, and membrane permeability to RF036, while exhibiting greatly enhanced solubility and stability. Inhibitor 3 effectively inhibited MMP-13-mediated osteoclastogenesis but spared collagenolysis, and thus represents a next-generation MMP-13 probe applicable for in vivo studies of breast cancer metastasis.

Methylpyrazole derivatives as RET inhibitor

The invention relates to a methylpyrazole derivative as an RET inhibitor, in particular to a compound as shown in a formula (I), a stereoisomer and pharmaceutically acceptable salt thereof, a preparation method and a pharmaceutical composition thereof. The compound of the formula (I) can be used for preventing or treating diseases mediated by abnormal RET activity.

Synthetic method of medical intermediate cycloalkanopyrimidinedione compound

The invention provides a synthetic method of a cycloalkanopyrimidinedione compound, and belongs to the technical field of organic synthesis. The method provided by the invention comprises the following steps of: taking a 2-methoxycarbonyl naphthenone comp

Synthesis and evaluation of novel fused pyrimidine derivatives as GPR119 agonists

A novel series of fused pyrimidine derivatives were designed, synthesized and evaluated as GPR119 agonists. Among them, cyclohexene fused compounds (tetrahydroquinazolines) showed greater GPR119 agonistic activities than did dihydrocyclopentapyrimidine and tetrahydropyridopyrimidine scaffolds. Analogues (16, 19, 26, 28, 42) bearing endo-N-Boc-nortropane amine and fluoro-substituted aniline exhibited better EC50 values (0.27–1.2 μM) though they appeared to be partial agonists.

Octahydropyrrolo[3,4-c]pyrrole derivatives and use thereof

The invention relates to octahydropyrrolo[3,4-c]pyrrole derivatives and a use thereof. The above compounds and a medicinal composition containing the compounds are used for suppressing an orexin receptor. The invention also relates to a method for preparing the compounds and the medicinal composition, and the use of the compounds and the medicinal composition in the treatment or prevention of orexin receptor related diseases.

Development of matrix metalloproteinase-13 inhibitors – A structure-activity/structure-property relationship study

A structure-activity/structure-property relationship study based on the physicochemical as well as in vitro pharmacokinetic properties of a first generation matrix metalloproteinase (MMP)-13 inhibitor (2) was undertaken. After systematic variation of inhi

BICYCLIC DERIVATIVE CONTAINING PYRIMIDINE RING, AND PREPARATION METHOD THEREFOR

The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-HT4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like.